Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO
Glycorex Transplantation AB (publ) announces that the first ABO-incompatible transplantation after treatment using the company’s product, Glycosorb® ABO, has been successfully performed in Argentina.
The transplantation was a living donor kidney transplantation, which is the primary application of Glycosorb® ABO. However, the product is also used to enable other ABO-incompatible organ transplants, including the liver and heart. In Argentina, over 270 kidney transplants from living donors were performed in 2023, nearly three times the number performed in Sweden and just under half of those in Germany. Both the treatments and the transplantation were free of complications, and the patient is doing well.
For more information, please contact:
Johan Nilsson, interim CEO
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 25 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. Product development and production takes place in the company’s own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,500 transplants in over 25 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.